Cite
HARVARD Citation
Bahl, A. et al. (n.d.). Final quality of life and safety data for patients with metastatic castration‐resistant prostate cancer treated with cabazitaxel in the UK Early Access Programme (EAP) (NCT01254279). BJU international. pp. 880-887. [Online].